✦ LIBER ✦

PS1-33 Safety and efficacy of ITF2357, an orally active histone deacetylase inhibitor in the treatment of systemic onset juvenile idiopathic arthritis

✍ Scribed by J. Vojinovic; N. Damjanov; A. Furlan; C. D’Urzo; G. Susic; S. Pasic; N. Iagaru; M. Stefan; C.A. Dinarello

Book ID: 116399595
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 44 KB
Volume: 52
Category: Article
ISSN: 1043-4666
DOI: 10.1016/j.cyto.2010.07.105

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and efficacy of oral ITF2357 in p

Safety and efficacy of oral ITF2357 in patients with active systemic onset juvenile idiopathic arthritis

✍ Jelena Vojinovic; Charles A. Dinarello; Antonio Furlan; Nemanja Damjanov; Carmin 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Safety and efficacy of an oral histone d

Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis

✍ Jelena Vojinovic; Nemanja Damjanov; Carmine D'Urzo; Antonio Furlan; Gordana Susi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 2 views

## Abstract ## Objective The current treatment options for systemic‐onset juvenile idiopathic arthritis (JIA) are methotrexate, steroids, and biologic agents. This study was undertaken to evaluate the safety of the orally active histone deacetylase inhibitor givinostat (ITF2357) and its ability to